Show simple item record

dc.contributor.authorPlummer, Ren
dc.contributor.authorLorigan, Paul Cen
dc.contributor.authorBrown, Een
dc.contributor.authorZaucha, Ren
dc.contributor.authorMoiseyenko, Ven
dc.contributor.authorDemidov, Len
dc.contributor.authorSoriano, Ven
dc.contributor.authorChmielowska, Een
dc.contributor.authorAndrés, Ren
dc.contributor.authorKudryavtseva, Gen
dc.contributor.authorKahatt, Cen
dc.contributor.authorSzyldergemajn, Sen
dc.contributor.authorExtremera, Sen
dc.contributor.authorde Miguel, Ben
dc.contributor.authorCullell-Young, Men
dc.contributor.authorCalvert, Hen
dc.date.accessioned2013-12-20T12:12:31Z
dc.date.available2013-12-20T12:12:31Z
dc.date.issued2013-09-17
dc.identifier.citationPhase I-II study of Plitidepsin and Dacarbazine as first-line therapy for advanced melanoma. 2013, 109 (6):1451-9 Br J Canceren
dc.identifier.issn1532-1827
dc.identifier.pmid23989947
dc.identifier.doi10.1038/bjc.2013.477
dc.identifier.urihttp://hdl.handle.net/10541/308815
dc.description.abstractThis phase I-II trial compared plitidepsin 1-h infusion alone or combined with dacarbazine (DTIC) 1-h infusion as front-line therapy for advanced melanoma.
dc.language.isoenen
dc.rightsArchived with thanks to British journal of canceren
dc.titlePhase I-II study of Plitidepsin and Dacarbazine as first-line therapy for advanced melanoma.en
dc.typeArticleen
dc.contributor.departmentNorthern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, NE7 7DN, UK.en
dc.identifier.journalBritish Journal of Canceren
html.description.abstractThis phase I-II trial compared plitidepsin 1-h infusion alone or combined with dacarbazine (DTIC) 1-h infusion as front-line therapy for advanced melanoma.


This item appears in the following Collection(s)

Show simple item record